AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20006528 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 40
Study 20006528 — intervention group
Group type: COMPARATOR
Intervention: Four-layer compression bandages alone (control)
Number of subjects: 40
Study 17323051 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis
Number of subjects: 3877
Study 17323051 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis in larger hospitals
Number of subjects: 3877
Study 15753963 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking using NMES (n=17)
Number of subjects: 31
Study 15753963 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps endurance exercise in the sitting position by NMES (n=14)
Number of subjects: 31
Study 12169903 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg before surgery)
Number of subjects: 58
Study 12169903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 9445490 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (ALLO; 40 mg/kg)
Number of subjects: 22
Study 9445490 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 22
Study 9886795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse/synchronization cyclophosphamide/apheresis
Number of subjects: 18
Study 9886795 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 18
Study 2516122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken formula
Number of subjects: 61
Study 2516122 — intervention group
Group type: COMPARATOR
Intervention: LAD formula
Number of subjects: 61
Study 981327 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline continued for eight months
Number of subjects: 0
Study 981327 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline withdrawn double-blind to placebo after two months
Number of subjects: 0
Study 981327 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline withdrawn overtly to no medication
Number of subjects: 0
Study 981327 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy from social workers
Number of subjects: 0
Study 31980512 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring with telemonitoring
Number of subjects: 2774
Study 31980512 — intervention group
Group type: COMPARATOR
Intervention: BP self-monitoring in addition to usual care
Number of subjects: 2774
Study 31380115 — intervention group
Group type: EXPERIMENTAL
Intervention: IQP-AE-103 (two dosages)
Number of subjects: 0
Study 31380115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29267300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min CC with 8 min rest (Group A)
Number of subjects: 143
Study 29267300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min CC with 4 min rest (Group B)
Number of subjects: 143
Study 29267300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min CC with 6 min rest (Group C)
Number of subjects: 143
Study 29267300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min CC with 8 min rest (Group D)
Number of subjects: 143
Study 25921965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 752
Study 25921965 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)-only therapy
Number of subjects: 752
Study 23375640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging (MBB; n=19)
Number of subjects: 57
Study 23375640 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE; n=18)
Number of subjects: 57
Study 23375640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM; n=20)
Number of subjects: 57
Study 21914906 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture task card protocol
Number of subjects: 22
Study 21914906 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol
Number of subjects: 22
Study 21914906 — intervention group
Group type: COMPARATOR
Intervention: Picture activity schedule protocol
Number of subjects: 22
Study 19371931 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiopexy combined with neoadjuvant GnRH therapy (1.2 mg/d nasal spray for 4 weeks)
Number of subjects: 24
Study 19371931 — intervention group
Group type: COMPARATOR
Intervention: Orchiopexy alone
Number of subjects: 24
Study 16750325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated chest wall irradiation (72 Gy in 1.2-Gy b.i.d. fractions)
Number of subjects: 108
Study 16750325 — intervention group
Group type: COMPARATOR
Intervention: Once-daily chest wall irradiation (60 Gy in 2-Gy q.d. fractions)
Number of subjects: 108
Study 15235331 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+P beverage (7.3% carbohydrate and 1.8% protein)
Number of subjects: 15
Study 15235331 — intervention group
Group type: COMPARATOR
Intervention: CHO beverage (7.3% carbohydrate)
Number of subjects: 15
Study 11728069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg body weight)
Number of subjects: 40
Study 11728069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9143081 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation with background facilitation
Number of subjects: 22
Study 9143081 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation
Number of subjects: 22
Study 9143081 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 8194141 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine infusion
Number of subjects: 21
Study 8194141 — intervention group
Group type: COMPARATOR
Intervention: Three-hourly subcutaneous bolus injections of morphine
Number of subjects: 21
Study 8194141 — intervention group
Group type: COMPARATOR
Intervention: Microinfusion set for subcutaneous infusion
Number of subjects: 21
Study 2890268 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 25 mg daily
Number of subjects: 50
Study 2890268 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (Lasix Retard, LR) 30 mg daily
Number of subjects: 50
Study 29341984 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of RV1 (early administration)
Number of subjects: 0
Study 29341984 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of RV1 (on-time administration)
Number of subjects: 0
Study 29341984 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of RV1 (late administration)
Number of subjects: 0
Study 29341984 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of RV1 (early administration)
Number of subjects: 0
Study 29341984 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of RV1 (on-time administration)
Number of subjects: 0
Study 29341984 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of RV1 (late administration)
Number of subjects: 0
Study 27573324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket PATH mobile health application
Number of subjects: 96
Study 27573324 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate use of Pocket PATH (n=23)
Number of subjects: 96
Study 27573324 — intervention group
Group type: EXPERIMENTAL
Intervention: Income meeting basic needs
Number of subjects: 96
Study 27573324 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer hospital stays
Number of subjects: 96
Study 27573324 — intervention group
Group type: EXPERIMENTAL
Intervention: Past technology experience
Number of subjects: 96
Study 26505522 — intervention group
Group type: EXPERIMENTAL
Intervention: Technologically delivered stigma intervention
Number of subjects: 0
Study 22943627 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellbeing therapy (WBT) based on personalized mobile technology
Number of subjects: 0
Study 22943627 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0
Study 20858040 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDI‐F cutoff score of 33 in North America
Number of subjects: 428
Study 20858040 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDI‐F cutoff scores of 33 and 34 in Europe
Number of subjects: 428
Study 18763690 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 0.2% zinc sulphate
Number of subjects: 0
Study 18763690 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (no zinc)
Number of subjects: 0
Study 16284462 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine (3TC) - stavudine (d4T) - IDV (800 mg three times daily)
Number of subjects: 139
Study 16284462 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP) - d4T - IDV (1000 mg three times daily)
Number of subjects: 139
Study 12028179 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program of muscle strengthening and balance retraining exercises, individually prescribed and delivered at home by trained health professionals.
Number of subjects: 1016
Study 10513804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice a day) for 12 months
Number of subjects: 72
Study 10513804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 9816009 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of tumor-infiltrating lymphocytes (TIL group)
Number of subjects: 13
Study 9816009 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control group)
Number of subjects: 13
Study 2201189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal clindamycin
Number of subjects: 67
Study 2201189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 387329 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg at bedtime)
Number of subjects: 0
Study 387329 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine
Number of subjects: 0
Study 387329 — intervention group
Group type: EXPERIMENTAL
Intervention: Methscopolamine
Number of subjects: 0
Study 387329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31950134 — intervention group
Group type: COMPARATOR
Intervention: 1000 IU/d vitamin D3
Number of subjects: 225
Study 31950134 — intervention group
Group type: COMPARATOR
Intervention: 2000 IU/d vitamin D3
Number of subjects: 225
Study 25876607 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (placebo-controlled trials)
Number of subjects: 977
Study 25876607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group in trials)
Number of subjects: 977
Study 28207168 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 1500
Study 28207168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 25544594 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise training
Number of subjects: 18
Study 23920939 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation technique (RT)
Number of subjects: 0
Study 23920939 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical music intervention (MMI)
Number of subjects: 0
Study 23920939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature landscape applications with music (NLAM)
Number of subjects: 0
Study 23920939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature landscape applications without music (NLAWM)
Number of subjects: 0
Study 23920939 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 21330034 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive and intensive treatment of cardiovascular risk factors
Number of subjects: 247
Study 21330034 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 247
Study 21330034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative survival rate
Number of subjects: 247
Study 19084453 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent split virus influenza vaccine
Number of subjects: 0
Study 19084453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16968577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of travoprost 0.004%/timolol 0.5% (T/T)
Number of subjects: 0
Study 16968577 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination of latanoprost 0.005%/timolol 0.5% (L/T)
Number of subjects: 0
Study 15519437 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster-Stratton parenting program (16-hour weekly intervention)
Number of subjects: 26
Study 15519437 — intervention group
Group type: COMPARATOR
Intervention: Control group (4-month wait list)
Number of subjects: 26
Study 11049793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (500 mg 4 times daily for 21 days)
Number of subjects: 35
Study 11049793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11049793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (500 mg q.i.d. for an additional 21 days)
Number of subjects: 35
Study 9486031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral peripheral iridectomy (PI)
Number of subjects: 48
Study 9486031 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Nd:YAG laser iridotomy (YAG PI)
Number of subjects: 48
Study 7933789 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol, 400-800 mg/day for 12 weeks
Number of subjects: 0
Study 7933789 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 80-160 mg/day for 12 weeks
Number of subjects: 0
Study 3739795 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent smoking relapse prevention treatment
Number of subjects: 0
Study 3739795 — intervention group
Group type: COMPARATOR
Intervention: Basic broad-spectrum stop-smoking program plus discussion control
Number of subjects: 0
Study 3739795 — intervention group
Group type: COMPARATOR
Intervention: Basic broad-spectrum stop-smoking program alone
Number of subjects: 0
Study 30448901 — intervention group
Group type: EXPERIMENTAL
Intervention: Solubilized eggshell membrane (S-ESM)
Number of subjects: 0
Study 30448901 — intervention group
Group type: COMPARATOR
Intervention: Gel with 20% type III/80% type I collagen
Number of subjects: 0
Study 29606694 — intervention group
Group type: EXPERIMENTAL
Intervention: MoGro mobile grocery program providing access to subsidized healthy foods and complementary events (fitness activities and cooking classes)
Number of subjects: 0
Study 29606694 — intervention group
Group type: EXPERIMENTAL
Intervention: MoGro mobile grocery program
Number of subjects: 0
Study 27094871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 units per week)
Number of subjects: 210
Study 24667381 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue liraglutide
Number of subjects: 0
Study 24667381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22645201 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 6 months
Number of subjects: 36
Study 22645201 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy prepubertal children)
Number of subjects: 36
Study 19960352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Exercise at 80% of Maximal Aerobic Speed (CE80)
Number of subjects: 14
Study 19960352 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Exercise at 110% of Maximal Aerobic Speed (IE110)
Number of subjects: 14
Study 19960352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Exercise at 60% of Maximal Aerobic Speed (CE60)
Number of subjects: 14
Study 19960352 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Exercise at 90% of Maximal Aerobic Speed (IE90)
Number of subjects: 14
Study 19960352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Exercise at 70% of Maximal Aerobic Speed (CE70)
Number of subjects: 14
Study 19960352 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Exercise at 100% of Maximal Aerobic Speed (IE100)
Number of subjects: 14
Study 19960352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Exercise (CE)
Number of subjects: 14
Study 19960352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Heart Rate (HR) during CE and IE
Number of subjects: 14
Study 19960352 — intervention group
Group type: EXPERIMENTAL
Intervention: CE80 versus IE110 association
Number of subjects: 14
Study 16458133 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg/day
Number of subjects: 60
Study 16458133 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 60
Study 16458133 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA and clopidogrel
Number of subjects: 60
Study 16458133 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 60
Study 16458133 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 60
Study 15100915 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient rehabilitation
Number of subjects: 53
Study 15100915 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient rehabilitation
Number of subjects: 53
Study 15100915 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient rehabilitation (but received in-patient treatment)
Number of subjects: 53
Study 15100915 — intervention group
Group type: COMPARATOR
Intervention: Overall rehabilitation
Number of subjects: 53
Study 11399219 — intervention group
Group type: EXPERIMENTAL
Intervention: Callback counselling
Number of subjects: 998
Study 11399219 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 998
Study 9416637 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate rating condition
Number of subjects: 0
Study 9416637 — intervention group
Group type: COMPARATOR
Intervention: Delayed rating condition
Number of subjects: 0
Study 7507201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose aprotinin
Number of subjects: 0
Study 7507201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 2879872 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg norfloxacin
Number of subjects: 886
Study 2879872 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg norfloxacin
Number of subjects: 886
Study 2879872 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ (160 mg/800 mg)
Number of subjects: 886
Study 2879872 — intervention group
Group type: COMPARATOR
Intervention: norfloxacin
Number of subjects: 886
Study 2879872 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMZ
Number of subjects: 886
Study 29847251 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA)
Number of subjects: 424
Study 29847251 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 424
Study 27283946 — intervention group
Group type: COMPARATOR
Intervention: SYN-004 (75-750 mg single dose)
Number of subjects: 64
Study 27283946 — intervention group
Group type: COMPARATOR
Intervention: SYN-004 (75-300 mg multiple doses every 6 hours for 7 days)
Number of subjects: 64
Study 24785002 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress group (exposed to a standardized psychosocial stress test - TSST)
Number of subjects: 48
Study 24785002 — intervention group
Group type: COMPARATOR
Intervention: Nonstress group (not exposed to stress)
Number of subjects: 48
Study 22126338 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic extract for 4 weeks
Number of subjects: 40
Study 22126338 — intervention group
Group type: COMPARATOR
Intervention: Nystatin for 4 weeks
Number of subjects: 40
Study 20023707 — intervention group
Group type: EXPERIMENTAL
Intervention: Early immunization (3 months) with 7-valent pneumococcal vaccine
Number of subjects: 28
Study 20023707 — intervention group
Group type: COMPARATOR
Intervention: Late immunization (9 months) with 7-valent pneumococcal vaccine
Number of subjects: 28
Study 20023707 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of anti-pneumococcal antibodies functionality through opsonophagocytic assay
Number of subjects: 28
Study 18554465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult gastroscope
Number of subjects: 103
Study 18554465 — intervention group
Group type: COMPARATOR
Intervention: Adult colonoscope
Number of subjects: 103
Study 15703253 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training sleep (after a night of sleep)
Number of subjects: 0
Study 15703253 — intervention group
Group type: COMPARATOR
Intervention: Post-training without intervening sleep (1 hour post-training)
Number of subjects: 0
Study 15703253 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between behavioral performance and brain activation after sleep
Number of subjects: 0
Study 12923723 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and cytotoxic agents (alternating schedule for 6 months)
Number of subjects: 174
Study 12923723 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and cytotoxic agents
Number of subjects: 174
Study 10940699 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAP
Number of subjects: 38
Study 10940699 — intervention group
Group type: COMPARATOR
Intervention: VLAP
Number of subjects: 38
Study 10940699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CLAP and VLAP
Number of subjects: 38
Study 9299907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise at 70% VO2max
Number of subjects: 20
Study 9299907 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 20
Study 9299907 — intervention group
Group type: COMPARATOR
Intervention: Cycling exercise at 55% VO2max
Number of subjects: 20
Study 8299437 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-injected insulin
Number of subjects: 20
Study 8299437 — intervention group
Group type: COMPARATOR
Intervention: Needle-injected insulin
Number of subjects: 20
Study 3105477 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (pancuronium bromide and Metubine sulfate with sedation)
Number of subjects: 33
Study 3105477 — intervention group
Group type: COMPARATOR
Intervention: Group S (allowed to shiver)
Number of subjects: 33
Study 16169887 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mammography
Number of subjects: 42760
Study 16169887 — intervention group
Group type: COMPARATOR
Intervention: Film mammography
Number of subjects: 42760
Study 16394080 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD group (untreated isolated GHD)
Number of subjects: 60